4D Molecular Therapeutics financials
$14.49−0.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $3.0M | $85.1M | $90.0K | $15.0K | $14.0K | $1.0K | $3.0K | $5.0K | $28.0K | — | $20.2M |
| Gross profit | $3.8M | $3.0M | $85.1M | $90.0K | $15.0K | $14.0K | $1.0K | $3.0K | $5.0K | $28.0K | — | $20.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% |
| Operating income | -$77.0M | -$73.6M | $14.7M | -$61.2M | -$59.5M | -$53.6M | -$56.1M | -$51.1M | -$42.5M | -$38.1M | — | -$14.0M |
| Net income | -$72.9M | -$68.8M | $19.4M | -$56.9M | -$54.7M | -$48.0M | -$49.7M | -$43.8M | -$35.0M | -$32.4M | — | -$10.3M |
| Net margin | −1929.0% | −2256.6% | 22.8% | −63195.6% | −364386.7% | −342657.1% | −4967100.0% | −1461433.3% | −699060.0% | −115717.9% | — | −50.8% |
| Diluted EPS | $-1.04 | $-1.01 | $0.30 | $-1.01 | $-0.98 | $-0.86 | $-0.89 | $-0.79 | $-0.63 | $-0.66 | — | $-0.24 |
| EBITDA | -$75.7M | -$72.4M | $15.9M | -$59.9M | -$58.3M | -$52.6M | -$55.0M | -$49.9M | -$41.3M | -$37.0M | $1.1M | -$13.0M |
| Operating cash flow | -$70.0M | -$68.1M | $28.6M | -$46.5M | -$43.4M | -$47.8M | -$45.9M | -$29.4M | -$30.2M | -$29.1M | -$24.6M | -$1.2M |
| Free cash flow | -$70.1M | -$68.1M | $28.5M | -$46.6M | -$44.1M | -$47.8M | -$46.8M | -$31.2M | -$30.6M | -$29.8M | -$25.2M | -$1.6M |
| Diluted shares | 70.3M | 68.1M | 63.9M | 56.1M | 55.9M | 55.7M | 55.7M | 55.6M | 55.3M | 49.3M | 43.2M | 42.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $70.4M | $72.5M | $60.2M | $48.6M | $77.2M | $133.5M |
| Short-term investments | $291.0M | $318.4M | $342.4M | $256.5M | $216.1M | $187.9M |
| Total debt | $19.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $492.6M | $512.9M | $566.7M | $424.0M | $473.6M | $515.7M |
| Total liabilities | $85.0M | $61.1M | $61.0M | $55.0M | $52.7M | $46.0M |
| Shareholders' equity | $407.7M | $451.8M | $505.7M | $369.0M | $420.9M | $469.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology